Pressemeddelelse fra LEO Pharma
Ballerup, Denmark, August 28, 2018 – On August 27 an extraordinary general meeting elected Olivier Bohuon as a new member of LEO Pharma’s Board of Directors. He will serve as the Board of Directors’ new vice chairman.
“I am excited to welcome Olivier Bohuon to LEO Pharma’s Board of Directors,” said Jukka Pertola, Chairman of LEO Pharma’s Board of Directors. “Olivier brings extensive strategic and commercial expertise in the global pharma industry. This will benefit LEO Pharma greatly as we are expanding into new innovative treatments in our ambition of being a global leader in medical dermatology,” Pertola continued.
“LEO Pharma is a company with a very strong vision. Its focus area of medical dermatology is strongly growing, highly competitive and benefiting from scientific advances in biotechnology. I am delighted to be able to help LEO Pharma succeed with its ambitious strategy,” said Olivier Bohuon.
Olivier Bohuon brings extensive experience in the global pharmaceutical and med-tech industry. He is board member of Smiths Group plc, senior independent director at Shire plc, supervisory board member at Virbac SA, and member of the National Pharmacy Academy and the Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew plc. Before that, he held positions as CEO at Laboratories Pierre Fabre, EVP, pharmaceutical products at Abbott Laboratories and SVP, director of European Commercial Operations at GlaxoSmithKline.
– ENDS –
+45 3140 6180
Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/olivier-bohuon-elected-to-leo-pharmas-board-of-directors?releaseId=13410631